| The chemical evolution of oligonucleotide therapies of clinical utility A Khvorova, JK Watts Nature biotechnology 35 (3), 238-248, 2017 | 1354 | 2017 |
| Silencing disease genes in the laboratory and the clinic JK Watts, DR Corey The Journal of pathology 226 (2), 365-379, 2012 | 640* | 2012 |
| Chemically modified siRNA: tools and applications JK Watts, GF Deleavey, MJ Damha Drug discovery today 13 (19-20), 842-855, 2008 | 589 | 2008 |
| Enhancer RNA facilitates NELF release from immediate early genes K Schaukowitch, JY Joo, X Liu, JK Watts, C Martinez, TK Kim Molecular cell 56 (1), 29-42, 2014 | 520 | 2014 |
| RNA therapeutics on the rise F Wang, T Zuroske, JK Watts Nature Reviews Drug Discovery 19, 441-442, 2020 | 322 | 2020 |
| Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide H Tran, MP Moazami, H Yang, D McKenna-Yasek, CL Douthwright, ... Nature medicine 28 (1), 117-124, 2022 | 204 | 2022 |
| Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ... Nature Communications 9, 2641, 2018 | 141 | 2018 |
| Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing GF Deleavey, JK Watts, T Alain, F Robert, A Kalota, V Aishwarya, ... Nucleic acids research 38 (13), 4547-4557, 2010 | 139 | 2010 |
| The NIH somatic cell genome editing program K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, ... Nature 592 (7853), 195-204, 2021 | 138 | 2021 |
| Oligonucleotide therapeutics: chemistry, delivery and clinical progress VK Sharma, JK Watts Future medicinal chemistry 7 (16), 2221-2242, 2015 | 131 | 2015 |
| Energetically important C− H··· F− C pseudohydrogen bonding in water: evidence and application to rational design of oligonucleotides with high binding affinity MY Anzahaee, JK Watts, NR Alla, AW Nicholson, MJ Damha Journal of the American Chemical Society 133 (4), 728-731, 2011 | 120 | 2011 |
| 2′-Fluoro-4′-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity JK Watts, N Choubdar, K Sadalapure, F Robert, AS Wahba, J Pelletier, ... Nucleic acids research 35 (5), 1441-1451, 2007 | 120 | 2007 |
| Chemical modification of siRNA GF Deleavey, JK Watts, MJ Damha Current Protocols in Nucleic Acid Chemistry 39 (1), 16.3. 1-16.3. 22, 2009 | 106 | 2009 |
| Differential stability of 2′ F-ANA• RNA and ANA• RNA hybrid duplexes: roles of structure, pseudohydrogen bonding, hydration, ion uptake and flexibility JK Watts, N Martín-Pintado, I Gomez-Pinto, J Schwartzentruber, G Portella, ... Nucleic acids research 38 (7), 2498-2511, 2010 | 102 | 2010 |
| Generation of novel hybrid aptamer–molecularly imprinted polymeric nanoparticles A Poma, H Brahmbhatt, HM Pendergraff, JK Watts, NW Turner Advanced Materials 27 (4), 750-758, 2015 | 101 | 2015 |
| Clinical status of duplex RNA JK Watts, DR Corey Bioorganic & medicinal chemistry letters 20 (11), 3203-3207, 2010 | 91 | 2010 |
| Studies on the hydrolytic stability of 2′-fluoroarabinonucleic acid (2′ F-ANA) JK Watts, A Katolik, J Viladoms, MJ Damha Organic & Biomolecular Chemistry 7 (9), 1904-1910, 2009 | 86 | 2009 |
| Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in Fuchs’ dystrophy J Hu, Z Rong, X Gong, Z Zhou, VK Sharma, C Xing, JK Watts, DR Corey, ... Human molecular genetics 27 (6), 1015-1026, 2018 | 84 | 2018 |
| 2′ F-Arabinonucleic acids (2′ F-ANA)—History, properties, and new frontiers JK Watts, MJ Damha Canadian Journal of Chemistry 86 (7), 641-656, 2008 | 84 | 2008 |
| 5′-Modifications improve potency and efficacy of DNA donors for precision genome editing KS Ghanta, Z Chen, A Mir, GA Dokshin, PM Krishnamurthy, Y Yoon, ... Elife 10, e72216, 2021 | 70 | 2021 |
Anastasia KhvorovaUMASS Medical SchoolVerified email at umassmed.edu
